Results 41 to 50 of about 2,408 (176)

Spectrum of cardiovascular manifestations in homozygous familial hypercholesterolemia

Journal of Marine Medical Society, 2023
Homozygous familial hypercholesterolemia (HoFH) is a rare, primarily an autosomal dominant genetic disorder that causes markedly elevated low-density lipoprotein (LDL) cholesterol levels predisposing patients to risk of developing premature ...
Nitin Bajaj, Balbir Singh, Ananthkrishnan Ramamoorthy, Arijit Kumar Ghosh   +3 more
doaj   +1 more source

Plasma Dilution After Myocardial Ischemia–Reperfusion Injury Promotes Cardiac Repair, Heart Performance, and Recovery of Motor Function and Endurance in Old Mice

Aging Cell, Volume 25, Issue 5, May 2026.
Plasma dilution at 24 h after I/R improved cardiac remodeling, function, and the physical performance of old male and female mice, through lowered markers of inflammation, fibrosis, reduction of cardiomyocytes' apoptosis, increase in their cell‐cycle re‐entry, and healthier profile of newly synthesized proteome, including the determinants of Jak/Stat ...
Joana Marie C. Cruz, Rana Alzalzalee, Hayden Yeung, Zainab Mahmood, Qile Yang, Negar Morshedian, Zachery R. Robinson, Karan R. Malhotra, Michael J. Conboy, Ahmad Reza Mazahery, Jose B. Nevado, Irina M. Conboy   +11 more
wiley   +1 more source

Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial Hypercholesterolemia

Acta Medica, 2003
The extracorporeal elimination of LDL-cholesterol could be performed using the classic non-selective centrifuge or membrane plasmapheresis. The modern methods are more selective and effective.
Milan Bláha
doaj   +1 more source

DELP Treatment on Vision and Retinal Microcirculation in Patients With Acute Ischemic Stroke: Report of Five Cases and Literature Review

Therapeutic Apheresis and Dialysis, Volume 30, Issue 2, Page 168-175, April 2026.
ABSTRACT Background The delipid extracorporeal lipoprotein filter from plasma (DELP) treatment can effectively reduce blood lipid, increase blood flow, and improve neurological deficits in patients with acute ischemic stroke (AIS). However, its effect on vision and retinal microcirculation in stroke patients has never been reported.
Ning Li, Ronghua Hong, Hua You, Feiping Xu, Qingjun Zhang, Yiwen Lin, Yuting Su, Danmei Lan, Lingjing Jin, Junhui She   +9 more
wiley   +1 more source

Effects of Immunoadsorption on Markers of Iron Metabolism: A Case Series

Journal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT Immunoadsorption selectively eliminates circulating antibodies in antibody‐mediated diseases. Iron deficiency is the most common cause of anemia; however, the potential role of immunoadsorption in contributing to iron depletion remains insufficiently established.
Noemi E. Ginthör, Tobias Niedrist, Gerold Schwantzer, Alexander H. Kirsch, Werner Ribitsch, Andras Deak, Michael Kolland, Daniel Leitinger, Kathrin Eller, Alexander R. Rosenkranz, Katharina Artinger   +10 more
wiley   +1 more source

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia

Lipids in Health and Disease, 2011
Background Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease.
Minichilli Fabrizio, Bigazzi Federico, Sbrana Francesco, Puntoni Mariarita, Ferdeghini Ezio, Sampietro Tiziana   +5 more
doaj   +1 more source

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Background Studies comparing treatment strategies based on initiation timing—such as starting PCSK9 inhibitor (PCSK9i) therapy sooner versus later after a myocardial infarction (MI)—are prone to immortal time bias. Clone‐censor‐weight methods can address these issues and allow the researcher to emulate a trial in which patients are assigned to
Thomas Cars, Stefan Gustafsson, Queenie Chan, Nafeesa Dhalwani, Shia T. Kent, Andrew Briggs, Chris P. Gale, Anselm Gitt, J. Wouter Jukema, Philippe Gabriel Steg, Johan Sundström, Stefan James, Emil Hagström, M. Alan Brookhart   +13 more
wiley   +1 more source

Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes

JACC: Case Reports, 2019
This case report describes a 50-year-old-woman from Southeast Asia with extensive atherosclerotic cardiovascular disease, found to have homozygous familial hypercholesterolemia caused by variants of uncertain significance in both the APOB and LDLR genes.
Robert Derenbecker, MD, Karan Kapoor, MD, Emily Brown, MGC, CGC, Thorsten Leucker, MD, PhD, Steven R. Jones, MD, Parvez M. Lokhandwala, MD, PhD, Kathleen H. Byrne, CRNP, Seth S. Martin, MD, MHS   +7 more
doaj   +1 more source

Building evidence for transfusion practice: A pilot study on bacterial adhesion and growth in red blood cell infusion sets

Transfusion, Volume 66, Issue 4, Page 689-699, April 2026.
Abstract Background Blood administration sets are changed after a prescribed time interval with variations in guidelines. In Canada, sets are changed every 4 h based on the theory of potential bacterial attachment. This study aimed to investigate whether bacteria adhere to the inner surfaces of blood administration sets during mimicked transfusions of ...
Zoya Versey, Yuntong Kou, Paula van Vliet, Donna L. Ledingham, Sandra Ramirez‐Arcos   +4 more
wiley   +1 more source

Is LDL apheresis a thing of the past?

South African General Practitioner, 2020
Patients with severe hypercholesterolaemia have a high lifetime risk for developing cardiovascular disease. These patients are traditionally treated with high-intensity statins and ezetimibe. Some patients are refractory to treatment and cannot achieve a desirable reduction in low-density lipoprotein cholesterol (LDL-C).
M Vally, R Khan, A Orchard
openaire   +2 more sources